Given these gaps and the imperative to inform future innovation, we conducted a national, multicenter, observational study to evaluate the real-world effectiveness and safety of first-line serplulimab-based regimens in a broader population of patients with advanced esophageal cancer, irrespective of PD-L1 expression or SCEC histologic subtype. Here, CD274 is linked to esophageal cancer.